Bayesian Optimal Designs for Phase I Clinical Trials

DOI10.1111/1541-0420.00069zbMath1210.62165OpenAlexW1972194651WikidataQ79257869 ScholiaQ79257869MaRDI QIDQ3079157

William F. Rosenberger, Inna Perevozskaya, Linda M. Haines

Publication date: 1 March 2011

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1111/1541-0420.00069

zbMATH Keywords

maximum tolerated dosesequential designconstrained optimal design

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Optimal statistical designs (62K05) Bayesian inference (62F15) Medical applications (general) (92C50) Sequential statistical design (62L05)

Related Items (24)

Optimal sequential designs in phase I studies ⋮ A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents ⋮ Sequential Two-stage D-optimality Sensitivity Test for Binary Response Data ⋮ Information in a two-stage adaptive optimal design ⋮ Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials ⋮ A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in Phase I clinical trials ⋮ Stochastic approximation and modern model-based designs for dose-finding clinical trials ⋮ Bayesian models and decision algorithms for complex early phase clinical trials ⋮ Approximate dynamic programming and its applications to the design of Phase I cancer trials ⋮ Adaptive Bayesian compound designs for dose finding studies ⋮ The augmentation of existing data for improving the path of steepest ascent ⋮ Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ Compound optimal designs for percentile estimation in dose-response models with restricted design intervals ⋮ Adaptive Design Optimization: A Mutual Information-Based Approach to Model Discrimination in Cognitive Science ⋮ Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs ⋮ Adaptive designs for selecting drug combinations based on efficacy-toxicity response ⋮ Convergence properties of sequential Bayesian \(D\)-optimal designs ⋮ A Semiparametric Sequential Algorithm for Estimation of Dose–Response Curve ⋮ Adaptive designs for dose-finding based on efficacy-toxicity response ⋮ Sequential Methods in Multi-Arm Clinical Trials ⋮ Random norming AIDS analysis of non-linear regression models with sequential informative dose selection ⋮ On optimal designs for clinical trials: an updated review ⋮ Penalized optimal designs for dose-finding

Cites Work

• Unnamed Item
• Asymptotic normality of maximum likelihood estimators from multiparameter response-driven designs
• Bayesian design for estimating the turning point of a quadratic regression
• Selection of Dose Levels for Estimating a Percentage Point of a Logistic Quantal Response Curve
• A Random Walk Rule for Phase I Clinical Trials
• The Equivalence of Constrained and Weighted Designs in Multiple Objective Design Problems
• Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers
• Optimum Experimental Designs for Multinomial Logistic Models
• A Curve‐Free Method for Phase I Clinical Trials
• Optimum Dose Levels when Males and Females Differ in Response
• Design of Experiment for Bioassay
• Sufficient conditions for extremum, penalty functions and regularity

This page was built for publication: Bayesian Optimal Designs for Phase I Clinical Trials